ReviewInternational journal of molecular sciences2025
Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Use of Anticoagulants as a Supportive Measure in Pulmonary Hypertension: A Narrative Review.Tuberculosis and respiratory diseases · 2026Article
- Review
- AI-based pulmonary artery to ascending aorta ratio on non-contrast CT for pulmonary hypertension: diameter vs. volume assessment.European heart journal. Imaging methods and practice · 2026Article
- Correlation of Thoracic HRCT Scores with Right Heart Mechanics and TAPSE/sPAP Ratio in Pulmonary Alveolar Proteinosis.Journal of clinical medicine · 2026Article
- Serum Pharmacochemistry-Guided DARTS-MS Profiling Reveals Potential Mechanisms ofInternational journal of molecular sciences · 2026Article
- Pulmonary Hypertension Associated with Severe Interstitial Pneumonia Successfully Treated with Inhaled Treprostinil.Internal medicine (Tokyo, Japan) · 2026Article
- Cellular Signalling Networks in High Altitude Pulmonary Hypertension: From Canonical Pathways to Emerging Targets.Cell proliferation · 2026Review
- Hypoxic Pulmonary Hypertension: Molecular Mechanisms and Clinical Research Advances.International journal of molecular sciences · 2026Review
- Vascular Remodelling in COPD: An In Silico Tool to Represent Pulmonary Haemodynamics in Obstructive Lung Disease.Annals of biomedical engineering · 2026Article
- Review
- Artificial Intelligence for the Identification of Vascular Imaging Biomarkers in COPD: Redefining Phenotypes and Enabling Precision Care.Journal of clinical medicine · 2025Article
- Features of Heart Failure with Preserved Ejection Fraction in Patients with Chronic Obstructive Pulmonary Disease and Systemic Sclerosis-Associated Interstitial Lung Diseases.Journal of personalized medicine · 2025Article
- Hsa_circ_0005623 is an indicator for pulmonary artery hypertension associated with congenital heart disease.Frontiers in cardiovascular medicine · 2025Article
- Exercise Dysfunction and Pulmonary Rehabilitation Strategies in COPD Patients at High-Altitudes: A Review.International journal of chronic obstructive pulmonary disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pulmonary hypertension associated with lung diseases and/or hypoxia is classified as group 3 in the clinical classification of pulmonary hypertension. The efficacy of existing selective pulmonary vasodilators for group 3 pulmonary hypertension is still unknown, and it is currently associated with a poor prognosis. The mechanisms by which pulmonary hypertension occurs include hypoxic pulmonary vasoconstriction, pulmonary vascular remodeling, a decrease in pulmonary vascular beds, endothelial dysfunction, endothelial-to-mesenchymal transition, mitochondrial dysfunction, oxidative stress, hypoxia-inducible factors (HIFs), inflammation, microRNA, and genetic predisposition. Among these, hypoxic pulmonary vasoconstriction and subsequent pulmonary vascular remodeling are characteristic factors involving the pulmonary vasculature and are the focus of this review. Several factors have been reported to mediate vascular remodeling induced by hypoxic pulmonary vasoconstriction, such as HIF-1α and mechanosensors, including TRP channels. New therapies that target novel molecules, such as mechanoreceptors, to inhibit vascular remodeling are awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.